Clinical Trials Logo

Metastatic Solid Tumor clinical trials

View clinical trials related to Metastatic Solid Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05863052 Active, not recruiting - Melanoma Clinical Trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Start date: January 31, 2022
Phase:
Study type: Observational

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

NCT ID: NCT05103358 Active, not recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT04706715 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

LAG3 PET Imaging in Advanced Solid Tumors

Start date: January 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.

NCT ID: NCT04579757 Active, not recruiting - Colorectal Cancer Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Start date: March 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

NCT ID: NCT04474470 Active, not recruiting - Clinical trials for Head and Neck Cancer

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Start date: September 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.

NCT ID: NCT04447651 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

PRISMM
Start date: September 17, 2020
Phase:
Study type: Observational [Patient Registry]

This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.

NCT ID: NCT04383210 Active, not recruiting - Breast Cancer Clinical Trials

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Start date: September 29, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

NCT ID: NCT03964727 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

TROPiCS-03
Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.

NCT ID: NCT03284502 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: May 22, 2017
Phase: Phase 1
Study type: Interventional

This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.